Your shopping cart is currently empty

BBI-355 is an oral, potent, and selective small molecule CHK1 inhibitor with an IC50 of 0.3 nM. It exhibits significant antitumor activity, both as a monotherapy and in combination with targeted therapies, across various ecDNA+ oncogene-amplified tumor models.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | BBI-355 is an oral, potent, and selective small molecule CHK1 inhibitor with an IC50 of 0.3 nM. It exhibits significant antitumor activity, both as a monotherapy and in combination with targeted therapies, across various ecDNA+ oncogene-amplified tumor models. |
| Synonyms | BBI355 |
| Molecular Weight | 377.40 |
| Formula | C19H19N7O2 |
| Cas No. | 2871056-82-3 |
| Smiles | O(C1=C(C(OC)=CC=C1)C2=CC(NC=3C=NC(C#N)=CN3)=NN2)[C@@H]4C[C@@H](N)C4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.